BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising symptom relief and tolerability.
BostonSight
Latest Content
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
Dompé's NAION program selected for FDA Commissioner’s National Priority Voucher Program
3
Q&A: Insights from Rajesh K. Rajpal, MD, on an incision-free keratoconus therapy
4
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial
5
.png "Optometry Times"){kind=logo}
